@article{83b9d3503eac4893ac3301c4fc5b9c22,
title = "Gene expression predicts dormant metastatic breast cancer cell phenotype",
abstract = "Background: Breast cancer can recur months to decades after an initial diagnosis and treatment. The mechanisms that control tumor cell dormancy remain poorly understood, making it difficult to predict which patients will recur and thus benefit from more rigorous screening and treatments. Unfortunately, the extreme rarity of dormant DTCs has been a major obstacle to their study. Methods: To overcome this challenge, we developed an efficient system to isolate and study rare dormant breast cancer cells from metastatic organs including bones, which represent a major site of metastasis. After isolation of cells from the long bones, we used single cell RNA-sequencing (scRNA-seq) to profile proliferative and dormant PyMT-Bo1 breast cancer cells. We also compared this signature to dormant versus proliferative tumor cells isolated from the lungs. Finally, we compared our dormant signature to human datasets. Results: We identified a group of genes including Cfh, Gas6, Mme and Ogn that were highly expressed in dormant breast cancer cells present in the bone and lung. Expression of these genes had no impact on dormancy in murine models, but their expression correlated with disease-free survival in primary human breast cancer tumors, suggesting that these genes have predictive value in determining which patients are likely to recur. Conclusions: Dormant breast cancer cells exhibit a distinct gene expression signature regardless of metastatic site. Genes enriched in dormant breast cancer cells correlate with recurrence-free survival in breast cancer patients.",
keywords = "Biomarkers, Breast cancer, Disseminated tumor cell, Dormancy, scRNA-seq",
author = "Qihao Ren and Khoo, {Weng Hua} and Corr, {Alexander P.} and Phan, {Tri Giang} and Croucher, {Peter I.} and Stewart, {Sheila A.}",
note = "Funding Information: This work was supported by NIH grants R01 AG059244, CA217208, (S.A.S.), an American Cancer Society Research Scholar Award (S.A.S.). The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702–5014, is the awarding and administrating acquisition office, and this was supported in part by the Office of the Assistant Secretary of Defense for Health Affairs, through the Breast Cancer Research Program, under award No. BC181712. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. We thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, MO., for the use of the WUCCI and Flow Cytometry Shared Resource, which provided imaging and FACS services, respectively. The Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant #P30 CA091842, Fashion Footwear Association of New York, and the Foundation for Barnes-Jewish Hospital Cancer Frontier Fund to S.A.S. TGP (1155678) is supported by a Fellowship from the National Health and Medical Research (NHMRC). WHK is supported by the UNSW Sydney Cellular Genomics Futures Institute. Elements of this work were supported by an NHMRC project grant. and Mrs. Janice Gibson and the Ernest Heine, Family Foundation (P.I. Croucher and T.G. Phan). Parts of this was also supported by the Emerson Collective (S.A.S.). Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = dec,
doi = "10.1186/s13058-022-01503-5",
language = "English",
volume = "24",
journal = "Breast Cancer Research",
issn = "1465-5411",
number = "1",
}